*PROFENAL Ophthalmic Solution is indicated for inhibition of intraoperative [[miosis]].
*On the day of [[surgery]], instill two drops into the [[conjunctival]] sac at three, two and one hour prior to [[surgery]]. Two drops may be instilled into the [[conjunctival]] sac every four hours, while awake, the day preceding [[surgery]].
<!--Off-Label Use and Dosage (Adult)-->
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
<!--Pediatric Indications and Dosage-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
<!--Off-Label Use and Dosage (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
<!--Contraindications-->
|contraindications=* PROFENAL is contraindicated in epithelial [[herpes simplex]] [[keratitis]] (dendritic [[keratitis]]) and in individuals hypersensitive to any component of the medication.
<!--Warnings-->
|warnings=* The potential exists for cross sensitivity to acetylsalicylic acid and other [[nonsteroidal anti-inflammatory drug]]s. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
*With [[nonsteroidal anti-inflammatory drug]]s, the potential exists for increased bleeding time due to interference with [[thrombocyte]] aggregation. There have been reports that ocularly applied [[nonsteroidal anti-inflammatory drug]]s may cause increased bleeding tendency of ocular tissues in conjunction with ocular [[surgery]].
====Precautions====
*General
:*Use of oral suprofen has been associated with a syndrome of acute [[flank pain]] and generally reversible [[renal insufficiency]], which may present as acute uric acid [[nephropathy]]. This syndrome occurs in approximately 1 in 3500 patients and has been reported with as few as one to two doses of a 200 mg capsule. If PROFENAL 1% Ophthalmic Solution is applied as two drops (1 mg suprofen) to one eye five times on the day prior to surgery and three times on the day of [[surgery]], the total applied dose over the two days would be about 25 times less than a single 200 mg oral dose. Do not touch dropper tip to any surface, as this may contaminate the solution.
*Ocular
:*Patients with histories of [[herpes simplex]] [[keratitis]] should be monitored closely. PROFENAL is contraindicated in patients with active herpes simplex [[keratitis]].
:*The possibility of increased ocular bleeding during surgery associated with [[nonsteroidal anti-inflammatory drug]]s should be considered.
<!--Adverse Reactions-->
<!--Clinical Trials Experience-->
|clinicalTrials=*Ocular
:*The most frequent adverse reactions reported are burning and stinging of short duration. Instances of discomfort, itching and redness have been reported. Other reactions occurring in less than 0.5% of patients include [[allergy]], [[iritis]], pain, [[chemosis]], [[photophobia]], irritation, and punctate epithelial staining.
*Systemic
:*Systemic reactions related to therapy were not reported in the clinical studies. It is known that some systemic absorption does occur with ocularly applied drugs, and that [[nonsteroidal anti-inflammatory drug]]s have been shown to increase [[bleeding time]] by interference with [[thrombocyte]] aggregation. It is recommended that PROFENAL be used with caution in patients with [[bleeding tendencies]] and those taking [[anticoagulants]].
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
<!--Drug Interactions-->
|drugInteractions=*Clinical studies with acetylcholine chloride revealed no interference, and there is no known pharmacological basis for such an interaction. However, with other topical nonsteroidal anti-inflammatory products, there have been reports that [[acetylcholine]] chloride and carbachol have been ineffective when used in patients treated with these agents.
*Interaction of PROFENAL with other topical ophthalmic medications has not been fully investigated.
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category C'''
*Reproductive studies have been performed in rabbits at doses up to 200 mg/kg/day and in rats at doses up to 80 mg/kg/day. In rats, doses of 40 mg/kg/day and above, and in rabbits, doses of 80 mg/kg/day and above, resulted in an increased incidence of fetal resorption associated with maternal toxicity. There was an increase in stillbirths and a decrease in postnatal survival in pregnant rats treated with suprofen at 2.5 mg/kg/day and above. An increased incidence of delayed parturition occurred in rats. As there are no adequate and well-controlled studies in pregnant women, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because of the known effect of [[nonsteroidal anti-inflammatory drug]]s on the fetal cardiovascular system (closure of [[ductus arteriosus]]), use during late pregnancy should be avoided.
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=*Suprofen is excreted in human milk after a single oral dose. Based on measurements of plasma and milk levels in women taking oral suprofen, the milk concentration is about 1% of the plasma level. Because systemic absorption may occur from topical ocular administration, a decision should be considered to discontinue nursing while receiving PROFENAL®, since the safety of suprofen in human neonates has not been established.
|useInPed=*Safety and effectiveness in pediatric patients have not been established.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
<!--Administration and Monitoring-->
|administration=* Topical
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
<!--Overdosage-->
|overdose====Acute Overdose===
*Overdosage will not ordinarily cause acute problems. If accidentally ingested, drink fluids to dilute.
===Chronic Overdose===
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
|mechAction=* Suprofen is one of a series of phenylalkanoic acids that have shown [[analgesic]], [[antipyretic]], and [[anti-inflammatory]] activity in animal inflammatory diseases. Its mechanism of action is believed to be through inhibition of the [[cyclooxygenase]] enzyme that is essential in the biosynthesis of [[prostaglandins]].
<!--Structure-->
|structure=* PROFENAL® (suprofen) 1% ophthalmic solution is a topical nonsteroidal anti-inflammatory product for ophthalmic use. Suprofen chemically is α -methyl-4-(2-thienylcarbonyl)benzeneacetic acid, with an empirical formula of C14H12O3S, and a molecular weight of 260.3. The chemical structure of suprofen is:
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
|PD=*[[Prostaglandins]] have been shown in many animal models to be mediators of certain kinds of intraocular [[inflammation]]. In studies performed on animal eyes, [[prostaglandins]] have been shown to produce disruption of the blood-aqueous humor barrier, [[vasodilatation]], increased vascular permeability, [[leukocytosis]], and increased [[intraocular pressure]].
*[[Prostaglandins]] appear to play a role in the miotic response produced during ocular [[surgery]] by constricting the [[iris]] sphincter independently of cholinergic mechanisms. In clinical studies, PROFENAL has been shown to inhibit the [[miosis]] induced during the course of [[cataract]] surgery. PROFENAL could possibly interfere with the [[miotic]] effect of intraoperatively administered [[acetylcholine]] chloride.
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
<!--Nonclinical Toxicology-->
|nonClinToxic=*In an 18-month study in mice, an increased incidence of benign hepatomas occurred in females at a dose of 40 mg/kg/day. Male mice, treated at doses of 2, 5, 10 and 40 mg/kg/day, also had an increased incidence of hepatomas when compared to control animals. No evidence of carcinogenicity was found in long term studies in doses as high as 40 mg/kg/day in the rat and mouse. Based on a battery of mutagenicity tests (Ames, micronucleus, and dominant lethal), suprofen does not appear to have mutagenic potential. Reproductive studies in rats at a dose of up to 40 mg/kg/day revealed no impairment of fertility and only slight reductions of fertility at doses of 80 mg/kg/day. However, testicular atrophy/hypoplasia was observed in a six-month dog study (at 80 mg/kg/day) and a 12-month rat study (at 40 mg/kg/day).
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
<!--How Supplied-->
|howSupplied=* Sterile ophthalmic solution, 2.5 mL in plastic DROP-TAINER® dispensers.
:*2.5 mL NDC 0065-0348-25
*Store at room temperature.
<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
<!--Precautions with Alcohol-->
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
<!--Brand Names-->
|brandNames=* PROFENAL®<ref>{{Cite web | title = PROFENAL suprofen solution | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8de2c303-5d99-46b6-ad6d-a4caadea3604 }}</ref>
<!--Look-Alike Drug Names-->
|lookAlike=<!--Drug Shortage Status-->
|drugShortage=
}}
{{PillImage
|fileName=No image.jpg
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
}}
'''Suprofen''' is an [[NSAID]] marketed in a 1% solution under the [[trade name]] '''Profenal'''.
<!--Pill Image-->
<!--Label Display Image-->
==Uses==
Suprofen was originally used as a [[tablet]] but has since been [[Discontinuation|discontinued]] in that form.<ref>http://www.fda.gov/ora/compliance_ref/cpg/cpgdrg/cpg460-200.html ''Guidance for FDA Staff and Industry Compliance Policy Guides Manual'' Sec. 460.200</ref> It is now used exclusively as a [[topical]] [[Ophthalmology|ophthalmic]] solution, typically to prevent [[miosis]] during and after ophthalmic [[surgery]].
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Suprofen is an NSAID that is FDA approved for the treatment of intraoperative miosis. Common adverse reactions include burning, stinging of the eyes, eye discomfort, itching, and redness.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Intraoperative Miosis
PROFENAL Ophthalmic Solution is indicated for inhibition of intraoperative miosis.
On the day of surgery, instill two drops into the conjunctival sac at three, two and one hour prior to surgery. Two drops may be instilled into the conjunctival sac every four hours, while awake, the day preceding surgery.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Suprofen in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Suprofen in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding FDA-Labeled Use of Suprofen in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Suprofen in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Suprofen in pediatric patients.
Contraindications
PROFENAL is contraindicated in epithelial herpes simplexkeratitis (dendritic keratitis) and in individuals hypersensitive to any component of the medication.
Warnings
The potential exists for cross sensitivity to acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
Use of oral suprofen has been associated with a syndrome of acute flank pain and generally reversible renal insufficiency, which may present as acute uric acid nephropathy. This syndrome occurs in approximately 1 in 3500 patients and has been reported with as few as one to two doses of a 200 mg capsule. If PROFENAL 1% Ophthalmic Solution is applied as two drops (1 mg suprofen) to one eye five times on the day prior to surgery and three times on the day of surgery, the total applied dose over the two days would be about 25 times less than a single 200 mg oral dose. Do not touch dropper tip to any surface, as this may contaminate the solution.
Ocular
Patients with histories of herpes simplexkeratitis should be monitored closely. PROFENAL is contraindicated in patients with active herpes simplex keratitis.
The most frequent adverse reactions reported are burning and stinging of short duration. Instances of discomfort, itching and redness have been reported. Other reactions occurring in less than 0.5% of patients include allergy, iritis, pain, chemosis, photophobia, irritation, and punctate epithelial staining.
Systemic
Systemic reactions related to therapy were not reported in the clinical studies. It is known that some systemic absorption does occur with ocularly applied drugs, and that nonsteroidal anti-inflammatory drugs have been shown to increase bleeding time by interference with thrombocyte aggregation. It is recommended that PROFENAL be used with caution in patients with bleeding tendencies and those taking anticoagulants.
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Suprofen in the drug label.
Drug Interactions
Clinical studies with acetylcholine chloride revealed no interference, and there is no known pharmacological basis for such an interaction. However, with other topical nonsteroidal anti-inflammatory products, there have been reports that acetylcholine chloride and carbachol have been ineffective when used in patients treated with these agents.
Interaction of PROFENAL with other topical ophthalmic medications has not been fully investigated.
Reproductive studies have been performed in rabbits at doses up to 200 mg/kg/day and in rats at doses up to 80 mg/kg/day. In rats, doses of 40 mg/kg/day and above, and in rabbits, doses of 80 mg/kg/day and above, resulted in an increased incidence of fetal resorption associated with maternal toxicity. There was an increase in stillbirths and a decrease in postnatal survival in pregnant rats treated with suprofen at 2.5 mg/kg/day and above. An increased incidence of delayed parturition occurred in rats. As there are no adequate and well-controlled studies in pregnant women, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because of the known effect of nonsteroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during late pregnancy should be avoided.
Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Suprofen in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Suprofen during labor and delivery.
Nursing Mothers
Suprofen is excreted in human milk after a single oral dose. Based on measurements of plasma and milk levels in women taking oral suprofen, the milk concentration is about 1% of the plasma level. Because systemic absorption may occur from topical ocular administration, a decision should be considered to discontinue nursing while receiving PROFENAL®, since the safety of suprofen in human neonates has not been established.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Geriatic Use
There is no FDA guidance on the use of Suprofen with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Suprofen with respect to specific gender populations.
Race
There is no FDA guidance on the use of Suprofen with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Suprofen in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Suprofen in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Suprofen in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Suprofen in patients who are immunocompromised.
Administration and Monitoring
Administration
Topical
Monitoring
There is limited information regarding Monitoring of Suprofen in the drug label.
IV Compatibility
There is limited information regarding IV Compatibility of Suprofen in the drug label.
Overdosage
Acute Overdose
Overdosage will not ordinarily cause acute problems. If accidentally ingested, drink fluids to dilute.
Chronic Overdose
There is limited information regarding Chronic Overdose of Suprofen in the drug label.
Suprofen is one of a series of phenylalkanoic acids that have shown analgesic, antipyretic, and anti-inflammatory activity in animal inflammatory diseases. Its mechanism of action is believed to be through inhibition of the cyclooxygenase enzyme that is essential in the biosynthesis of prostaglandins.
Structure
PROFENAL® (suprofen) 1% ophthalmic solution is a topical nonsteroidal anti-inflammatory product for ophthalmic use. Suprofen chemically is α -methyl-4-(2-thienylcarbonyl)benzeneacetic acid, with an empirical formula of C14H12O3S, and a molecular weight of 260.3. The chemical structure of suprofen is:
File:Suprofen01.pngThis image is provided by the National Library of Medicine.
Prostaglandins appear to play a role in the miotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanisms. In clinical studies, PROFENAL has been shown to inhibit the miosis induced during the course of cataract surgery. PROFENAL could possibly interfere with the miotic effect of intraoperatively administered acetylcholine chloride.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Suprofen in the drug label.
Nonclinical Toxicology
In an 18-month study in mice, an increased incidence of benign hepatomas occurred in females at a dose of 40 mg/kg/day. Male mice, treated at doses of 2, 5, 10 and 40 mg/kg/day, also had an increased incidence of hepatomas when compared to control animals. No evidence of carcinogenicity was found in long term studies in doses as high as 40 mg/kg/day in the rat and mouse. Based on a battery of mutagenicity tests (Ames, micronucleus, and dominant lethal), suprofen does not appear to have mutagenic potential. Reproductive studies in rats at a dose of up to 40 mg/kg/day revealed no impairment of fertility and only slight reductions of fertility at doses of 80 mg/kg/day. However, testicular atrophy/hypoplasia was observed in a six-month dog study (at 80 mg/kg/day) and a 12-month rat study (at 40 mg/kg/day).
Clinical Studies
There is limited information regarding Clinical Studies of Suprofen in the drug label.
How Supplied
Sterile ophthalmic solution, 2.5 mL in plastic DROP-TAINER® dispensers.
2.5 mL NDC 0065-0348-25
Store at room temperature.
Storage
There is limited information regarding Suprofen Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Suprofen
|?Pill Name
|?Drug Name
|?Pill Ingred
|?Pill Imprint
|?Pill Dosage
|?Pill Color
|?Pill Shape
|?Pill Size (mm)
|?Pill Scoring
|?NDC
|?Drug Author
|format=template
|template=DrugPageImages
|mainlabel=-
|sort=Pill Name
}}
